Chris Ryan

2 days ago | onclive.com | Chris Ryan

NewsArticleApril 22, 2025 Oncodetect detects up to 200 ctDNA variants, providing a "detected" or "not detected" result and quantitative data for clinical decision-making. The test aids in adjuvant therapy decisions, treatment response evaluation, and monitoring for disease recurrence in solid tumor patients. Exact Sciences highlights the test's role in transforming cancer care by offering critical insights post-surgery and definitive therapy, enabling personalized care.

3 days ago | onclive.com | Chris Ryan

China’s National Medical Products Administration has accepted a supplemental new drug application (sNDA) seeking the approval of repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic solid tumors harboring NTRK gene fusions who have either progressed following prior therapies or have no satisfactory alternative treatment options.1 Repotrectinib was evaluated in patients with NTRK gene fusion–positive advanced solid tumors in the phase 1/2 TRIDENT-1...

1 week ago | onclive.com | Chris Ryan

The United Kingdom’s (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has approved belantamab mafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy; and in combination with pomalidomide (Pomalyst) and dexamethasone (BPd) for patients with relapsed/refractory multiple myeloma who have received at least 1 prior therapy, including...

1 week ago | onclive.com | Chris Ryan

Treatment with the off-the-shelf, targeted, cell-based immunotherapy Bria-IMT (SV-BR-1-GM) in combination with immune checkpoint inhibition led to overall survival (OS) outcomes that exceeded historical data for sacituzumab govitecan-hziy (Trodelvy) in heavily pretreated patients with metastatic hormone receptor (HR)–positive breast cancer, according to data from a phase 2 trial (NCT03328026).1,2 Findings showed that patients treated with Bria-IMT plus retifanlimab (Zynyz; n = 25) experienced...

1 week ago | onclive.com | Chris Ryan

Adjuvant durvalumab (Imfinzi) was not associated with a reduction in the frequency of relapse or alterations in the patterns of relapse compared with placebo in patients with resected stage IB to IIIA non–small cell lung cancer (NSCLC) who did not harbor EGFR or ALK alterations, irrespective of PD-L1 status, according to data from an analysis of the phase 3 CCTG BR.31 trial (NCT02273375).1 Findings presented at the 2025 European Lung Cancer Congress showed that in all patients without EGFR or...